B. Metzler seel. Sohn & Co. AG Makes New Investment in Stryker Corporation $SYK

Key Points

• B. Metzler seel. Sohn & Co. AG initiated a Stryker position by purchasing 120,896 shares valued at approximately $38.1 million. Institutional investors collectively own 77.09% of the company.
• Stryker reported quarterly EPS of $3.69, beating estimates by $0.20, while revenue rose 9.4% year over year to $6.59 billion. The company issued full-year 2026 EPS guidance of $14.95–$15.10.
• Insiders sold 665,370 shares worth about $216.2 million over the past 90 days, including a $96.8 million sale by Director Ronda E. Stryker. Despite the selling, analysts maintain a “Moderate Buy” consensus with an average price target of $386.28.

B. Metzler seel. Sohn & Co. AG bought a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 120,896 shares of the medical technology company's stock, valued at approximately $38,063,000.

A number of other hedge funds and other institutional investors have also modified their holdings of SYK. VanderPol Investments L.L.C. raised its position in Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock worth $732,000 after purchasing an additional 28 shares during the last quarter. KCM Investment Advisors LLC boosted its position in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after buying an additional 28 shares during the last quarter. Rossby Financial LCC increased its stake in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after buying an additional 28 shares during the period. Tcfg Wealth Management LLC raised its position in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after acquiring an additional 29 shares during the last quarter. Finally, West Michigan Advisors LLC raised its position in shares of Stryker by 0.4% during the fourth quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company's stock worth $2,631,000 after acquiring an additional 30 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 665,370 shares of company stock worth $216,238,501. Company insiders own 4.60% of the company's stock.

Stryker Price Performance

SYK opened at $327.97 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market cap of $125.80 billion, a P/E ratio of 33.99, a P/E/G ratio of 2.17 and a beta of 0.76. The company has a fifty day simple moving average of $326.64 and a 200 day simple moving average of $332.66.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is 36.48%.

Wall Street Analyst Weigh In

SYK has been the topic of several recent research reports. BMO Capital Markets initiated coverage on Stryker in a report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price target on the stock. Piper Sandler dropped their price objective on Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Canaccord Genuity Group cut their target price on shares of Stryker from $435.00 to $400.00 and set a "buy" rating on the stock in a research report on Friday, May 1st. Truist Financial raised their target price on shares of Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a research note on Friday, July 31st. Finally, Needham & Company LLC lowered their price target on shares of Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source